Victrelis Articles
Australia to subsidize groundbreaking hepatitis C drugs under PBS
19 February 2013
First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe
20 December 2012
Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status
21 October 2012
Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market
7 June 2012
NICE backs Merck & Co hep C drug Victrelis
9 March 2012
Dendreon cashes in Victrelis royalty
8 December 2011
Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice
9 October 2011
Merck & Co gets EU approval for Victrelis; Pfizer withdraws Macugen indication extension
20 July 2011
Most US clinicians plan to prescribe Incivek and Victrelis for treatment-naive hep C patients
5 July 2011
Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy
23 May 2011
Hepatitis C market rivals Merck & Co and Roche in marketing pact for newly-approved boceprevir
18 May 2011
Merck & Co’s Victrelis and Vertex’ telaprivir get unanimous backing from FDA advisory panel for chronic hep C
29 April 2011
Showing 1-22 of 22 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
